The SYNERGY-NASH trial included additional histologic assessments to demonstrate the efficacy of tirzepatide for MASH improvement without worsening of fibrosis compared to placebo, an endpoint endorsed by the Food and Drug Administration
doi: 10.1002/phar.2797 [PubMed] 37259844 Johannessen Landmark C, Eyal S, Burns ML, Franco V, Johannessen SI
QuickMDs hassle-free online consultations make getting the prescriptions you need simple
Plaintiffs are seeking compensation for the following damages: Medical Expenses
When youre eager to start a family, supporting fertility health is not just moms responsibilityits dads, too
Novo in July urged the PTAB to sanction Mylan for what it called harassing, duplicative litigation in its challenges to the 462 patent